Theraclone Sciences, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Seattle WA Uruguay (2004)
Status: Left NME R&D (2017)

Organization Overview

First Clinical Trial
2011
NCT01390025
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

tcn-032 (2 trials)

Drugs in Phase 1 Trials (1)

tcn-202 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cytomegalovirus Infections (Phase 1)

Influenza, Human (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2